March 27, 2020
Aquavit filed a new patent application with the United States Patent and Trademark Office. The patent covers novel methods for detecting allergic reactions in subjects using Aquavit’s proprietary microchannel technology.
In general, to diagnose an allergy, an allergist uses a skin prick test (SPT) to measure the presence of IgE antibodies for the suspected allergy. During the test, the allergist places a drop of allergen solution on the subject's forearm or back. The doctor would use a small needle to gently prick the skin to allow the solution to enter below the skin surface. The SPT is generally not painful and no occurrences of bleeding. A positive allergic result is indicated by a wheal, a raised bump surrounded by a small circle of itchy red skin. But, a large wheal is more likely to indicate a true allergy but the size is not always an accurate predicative. Aquavit’s technology intends to change this paradigm by introducing its novel delivery device technology to detect and diagnose allergies in a more reliable, effective and highly accurate manner.
Aquavit recently filed patent applications pertaining to its drug delivery platforms across immunology, dermatology and nutraceuticals and has been a pioneer in personalized medicine. “Aquavit’s proprietary microchannel delivery technology offers a platform to precisely deliver allergens to the epidermal and dermal skin layers that can provide highly accurate and personalized diagnosis for customized allergies”, says Sai Sankar, Aquavit’s Chief Biomedical Engineer.
Aquavit’s microchannel technology overcomes the existing problems of diagnoses of allergies while offering higher patient compliance, reliable and accurate methods to detect allergies that are normally associated with commercially available Skin Prick Tests. A related technology is currently used in Aquavit’s highly acclaimed AQUAGOLD® fine touch™ device. AQUAGOLD® is currently used by many medical professionals to micro-inject drugs and biologics into the dermal and epidermal skin layers for dermatological applications.
“It has been an exciting phase at Aquavit as we are actively working on bringing these innovative technologies to the market while focusing on the unmet clinical needs. We strongly believe that our modern technology has the potential to positively impact personalized healthcare”, says Sobin Chang, MPH, Aquavit’s Chief Executive Officer.
About Aquavit Pharmaceuticals, Inc.
Aquavit Pharmaceuticals, Inc. is a high-tech pharmaceutical company that provides a comprehensive range of innovative pharmaceutical, biotech and medical device technologies. Aquavit Pharmaceuticals, Inc. focuses on personalized medicine to improve patients' health, maximize the efficiency of our medical community, and support the pharmacoeconomics of payers.
Additional information about Aquavit can be found at www.aquavitpharma.com.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting device approvals, acceptance and demand for new products, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.